PharmaNest Inc. announced today a multi-institutional research collaboration with Virginia Commonwealth University (VCU) and the National Institutes of Health (NIH) to confirm the prognostic performance of artificial intelligence (AI) powered digital pathology biomarkers in metabolic dysfunction-associated steatotic liver disease (MASLD) in a retrospective cohort of 1,765 patients with MASH (NASH CRN DB2 Cohort)
Read More